Synthesis, tautomeric structure and antimicrobial activity of 3-arylhydrazono-4-phenyl-[1, 2, 4]-triazepino[2, 3-a]quinazoline-2, 7(1H)-diones

Article abstract of DOI:10.3390/molecules17078483

A simple strategy for the synthesis of the hitherto unreported 3-arylazo-4- phenyl- [1, 2, 4]triazepino[2, 3-a]quinazoline-2, 7(1H)-diones is described. Spectral data indicated that the studied compounds exist predominantly in the hydrazone tautomeric form. The antimicrobial activity of the newly synthesized compounds was also evaluated. The results indicated that some of these compounds have moderate activity towards bacteria.

Full text of DOI:10.3390/molecules17078483

Molecules 2012, 17, 8483-8493; doi:10.3390/molecules17078483
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Synthesis, Tautomeric Structure and Antimicrobial Activity of
3-Arylhydrazono-4-phenyl-[1,2,4]-triazepino[2,3-a]quinazoline-
2,7(1H)-diones
Thoraya Abdel Reheem Farghaly 1, Mastoura Mohamed Edrees 2,† and
Mosselhi Abdelnabi Mosselhi 1,3,
*
1
Department of Chemistry, Faculty of Science, University of Cairo, Giza 12311, Egypt;
E-Mail: Thoraya-f@hotmail.com
2
Department of Organic Chemistry, National Organization for Drug Control and Research (NODCAR),
Giza 12311, Egypt; E-Mail:mmohamededrees@yahoo.com
3
Department of Chemistry, Faculty of Science, Taif University, Taif-888, Saudi Arabia
†
Present address: Department of Chemistry, Faculty of Science, King Khalid University,
P.O. Box 9004, ABHA-61413, Saudi Arabia.
* Author to whom correspondence should be addressed; E-Mail: mosselhi2008 @hotmail.com.
Received: 24 May 2012; in revised form: 25 June 2012 / Accepted: 3 July 2012 /
Published: 13 July 2012
Abstract: A simple strategy for the synthesis of the hitherto unreported 3-arylazo-4-
phenyl- [1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-diones is described. Spectral data
indicated that the studied compounds exist predominantly in the hydrazone
tautomeric form. The antimicrobial activity of the newly synthesized compounds was also
evaluated. The results indicated that some of these compounds have moderate activity
towards bacteria.
Keywords: azo-hydrazone; tautomerism; [1,2,4]triazepino[2,3-a]quinazolindione;
anti-microbial activity

Molecules 2012, 17
8484
1. Introduction
4(3H)-Quinazolinone has to be the most used heterocycle in medicinal chemistry [1–3] and it is
considered as a key building block for natural alkaloids [4]. A wide spectrum of biological effects is
reported for compounds containing the quinazoline ring system. For example, many quinazoline
derivatives show antifungal [5], antitoxoplasmosis [6], anti-HIV-I agent [7], antitumour [8–10],
anti-allergic and antihypertensive properties [11]. They also have been used to prevent ocular
inflammatory reactions [12]. 2-Thioxo-4(1H)-quinazolinones are important derivative of quinazolinones
found to possess a variety of bioactivities and are good precursors for the synthesis of fused
quinazolines [13–15]. 2,3-Diaminoquinazolinone is reported to be the key for synthesis of derivatives
of thiazolo[4,3-b]benzothiazole, thiazolo[3',4':2,3], [1,2,4]-triazolo[5,1-b]-, {triazino[3,2-b]- and
triazepino[3,2-b]}-quinazolines [16]. 2-Thioxo-1H-4-quinazolinones are also versatile intermediates
for fused heterocyclo quinazolinones like 2-phenyl-5H-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one,
3-(4-bromophenyl)-2H,6H-[1,3,4]thiadiazino-[2,3-b]quinazolin-6-one, 4-amino-2-phenyl-3a,4-dihydro-
2H-thiazolo[3,2a]quinazoline -1,5-dione and 2-phenyl-[1,3,4]thiadiazino[2,3-b]quinazoline-3,6(2H,4H)-
dione [17].
It has been reported recently that the azo-hydrazone tautomerism of diazonium coupling products of
acyclic and heterocyclic active methylene compounds in both ground and excited states is useful in the
field of material sciences [18–24].
Due to the forgoing importance of quinazoline derivatives and as a part of our program of studies
on the chemistry of bioactive molecules and azo-hydrazone tautomerism [18–24], it was thought
interesting to study the synthesis of 4-phenyl-1,3-dihydro[1,2,4]triazepino[2,3-a]quinozalin-2,7-dione
(4) (Scheme 1) and its reaction with diazonium salts 5 in an attempt to synthesize the respective title
compounds, 3-arylhydrazino-4-phenyl-[1,2,4]triazepino[2,3-a]quinazolin-2,7(1H)-diones, 6 (Scheme 2)
and to study their tautomeric structures. This is because such products can have one or more of the
four tautomeric structures A–D shown in Figure 1. In addition, the products 6 obtained were tested for
their biological activity which is also reported.
Scheme 1. Synthesis of 4-phenyl-1,3-dihydro[1,2,4]triazepino[2,3-a]quinozalin-2,7-dione (4).
O
NH2
N
PhCOCH2COOEt
+
2
N
NH2
1
AcOH
-H2O, -EtOH
H
O
N
O
N
O
Ph
O
N
N
N
N
N
N
Ph
H
4
3

Molecules 2012, 17
Scheme 2. Synthesis of 3-arylhydrazino-4-phenyl-[1,2,4]triazepino[2,3-a]quinazolin-
8485
2,7(1H)-dione (6a–j).
O
Ph
O
N
N
N
Ar-N=N-Cl
5
+
N
H
4
NaOH
O
Ph
H
O
N
N
Ph
N
N
N
N
N
N
Ar
N
N
N
Ar
N
O
H
N
H
O
H
6A
6B
O
N
Ph
O
Ph
N
N
N
N
N
N
N
H
N
Ar
N
Ar
N
O
H
O
H
H
6D
6C
O
N
Ph
H
N
N
N
N
Ar
N
O
H
6E
Ar = X-C6H4
X : a, 4-OCH3; b, 4-CH3; c, 3-CH3; d, H; e, 3-Cl; f, 4-Cl; g, 3-NO2; h, 4-NO2;
i, 4-COCH3; j, 4-COOEt
Figure 1. Four tautomeric structures A–D of 4.
O
Ph
H
O
Ph
N
N
N
N
N
N
N
N
O
H
O
4A
H
4B
H
O
O
N
Ph
OH
Ph
N
N
N
N
N
N
N
OH
4D
4C

Molecules 2012, 17
8486
2. Results and Discussion
The starting 4-phenyl-1,3-dihydro-[1,2,4]triazepino[2,3-a]quinazoline-2,7-dione 4 was prepared by
condensation of 2,3-diamino-quinazolin-4-one 1 [25] with ethyl benzoylacetate 2 in acetic acid under
1
reflux. The structure of 4 was indicated by its elemental and spectral (IR, H-NMR and MS) analyses
(see the experimental section). As shown in Scheme 1, the reaction of 1 with 2 could in principle yield
4 and/or its isomer, namely, 2-phenyl-3,5-dihydro[1,2,4] triazepino[2,3-a]quinazoline-4,7-dione (3),
but the latter isomeric structure was discarded. because condensation reactions of ethyl benzoylacetate
with C,N-1,2-diaminoheterocycles thus far studied were reported to be regioselective and lead to
products that result from nucleophilic attack of the N-NH2 and the C-NH2 groups at the keto and ester
carbonyl groups of the β-keto ester, respectively to give the corresponding fused 4-oxo-1,2,4-
triazepine derivatives [26–28]. This regioselectivity was substantiated by X-ray crystallographic
analysis in some cases [28] and by spectral data [26–28].
The structure 4 can exist in one of the possible tautomeric forms 4A–D as shown in Figure 1. The
1
isomeric form 4A is the predominant one based on the spectral data (MS, H-NMR and IR). For
example, the 1H-NMR spectrum revealed three characteristic signals near  4.52, 7.38–8.22 and 13.15
which are assignable to CH2, C6H5 and the ring NH protons, respectively. Also, the mass spectrum of
compound 4 showed the molecular ion peak at m/z 304, which is consistent with its structural formula.
Reaction of 4 with diazotized anilines in basic medium afforded the respective arylazo derivatives 6
(Scheme 2). The mass spectra of the latter products revealed the molecular ion peaks at the expected
m/z values and their elemental analyses data were consistent with their assigned structures. The
infrared spectral data of compounds 6 (see Experimental) seem to be consistent more with the
hydrazone tautomeric form 6A rather than the other tautomeric forms 6B–E (Scheme 2). For example,
all compounds exhibit two carbonyl bands in the regions 1715–1681 and 1698–1643 cm−1
corresponding to the stretching vibrations of the pyrimidinone and the 1,2,4-triazepinone carbonyl
groups, respectively. The observed wave number of the latter CO stretching band in compounds 6
seems to result from the possible strong hydrogen bond with the hydrazone NH and conjugation with
the C=N double bond as required by the hydrazone form 6A (Scheme 2) [29].
To elucidate the actual tautomeric form of the studied compounds 6, we investigated their electronic
absorption spectra. The data are summarized in Table 1. As shown, each of compounds 6 in dioxane
exhibits three characteristic absorption bands in the regions 385–346, 328–248 and 257–231 nm. Such
an absorption pattern is similar to that of typical hydrazone chromophore [23,24]. Furthermore, the
spectrum of 6d, taken as a typical example of the series studied was recorded in variety solvents with
different polarities. The spectra obtained showed little, if any, shift (Table 1).
The small shifts in λmax of 6d in different solvents are due to solute-solvent interaction. In
agreement with this conclusion, is the observation that the spectra of arylhydrazones derived from the
reaction of quinones with N-alkyl-N-phenylhydrazine, unlike those of o- and p-hydroxyazo
compounds, are largely independent of the solvent polarity [30]. This finding, while it excludes the azo
tautomeric forms 6B, 6D and 6E, indicates that each of compounds 6 exist in one tautomeric form,
namely 6A (Scheme 2).

Molecules 2012, 17
Table 1. UV Spectra of 3-arylhydrazono-4-phenyl-1H-[1,2,4]triazepino[2,3-a]quinazolin-
8487
2,7-diones 6a–j in dioxane.
Compd. No.
max (log )
6a
6b
6c
385 (3.72), 321 (4.22), 257 (4.63)
381 (4.52), 260 (4.57), 231 (4.78)
375 (4.02), 282 (4.82), 247 (4.81)
370 (4.45), 248 (4.63)
372 (4.25), 286 (4.26), 231 (4.55)
372 (4.10), 328 (4.39), 233 (5.13)
346 (3.62), 267 (4.78), 232 (5.01)
383 (4.62), 260 (4.54), 234 (4.80)
372 (3.94), 260 (3.68), 235 (4.01)
381 (4.52), 260 (4.57), 231 (4.78)
6d a)
6e
6f
6g
6h
6i
6j
a)
Solvent max (log): acetic acid 370 (4.36), 248 (4.00); acetonitrile 370 (3.80), 246 (4.11); DMF
367 (4.01), 247 (4.14); ethanol 371 (3.60), 249 (3.70).
2.1. Anti-Microbial Activity
In vitro anti-microbial screening of compounds 4 and 6a–j prepared in this study was carried out
using two bacteria species, including a Gram negative bacterium, Escherichia coli (RCMB 000103)
(EC) and a Gram positive bacterium, Staphylococcus aureus (RCMB 000106) (SA) and two fungal
strains, namely Aspergillus fumigatus (RCMB 002003) (AF) and Candida albicans (RCMB 005002)
(CA) using the agar diffusion well method (see Experimental). The microorganisms were tested against
the activity of solutions of concentrations of 1.0 mg/mL of each compound in dimethylsulfoxide
(DMSO) and using an inhibition zone diameter in cm (IZD) as criterion for the antimicrobial activity.
The fungicide amphotericin B and the bactericide tetracycline were used as references to evaluate the
potency of the tested compounds under the same conditions. The results, depicted in Table 2, showed
that compounds 6a, e, h–j displayed moderate activities against E. coli and S. aureus, while, none of
the tested compounds have any activity against A. fumigatus and C. albicans. These biological activities
of compounds 6a–j are far less than the studied reference drugs (tetracycline and amphotericin B).
Table 2. Antimicrobial Activity of the newly synthesized compounds.
Microorganism/IZD (mm/mg sample) *
Cpd. no.
EC(G−)
0.0
00
SA (G+)
0.0
9
AF
0.0
00
0.0
0.0
00
00
00
00
00
00
00
00
--
CA
0.0
0.0
0.0
0.0
00
00
00
00
00
00
00
00
--
Control (DMSO)
4
6a
12
11
6b
00
00
6c
00
00
6d
00
00
6e
13
12
6f
00
00
6g
9
00
6h
11
12
6i
11
11
6j
12
12
Te **
Am **
31
29
--
--
17
20
* IZD, inhibition zone diameter, ** Te = Tetracycline used as standard antibacterial agent and
** Am = Amphotericin B used as standard antifungal agent.

Molecules 2012, 17
8488
3. Experimental Section
3.1. General
Melting points were determined on a Gallenkamp apparatus and are uncorrected. IR spectra were
recorded in potassium bromide pellets using Perkin Elmer FTIR 1650 and Pye-Unicam SP300 infrared
1
13
spectrophotometers. H-NMR and C-NMR spectra were recorded in deuterated dimethyl sulfoxide
(DMSO-d6) using a Varian Gemini 300 NMR spectrometer. Mass spectra were recorded on a
GCMS-QP 1000 EX Shimadzu and GCMS 5988-A HP spectrometers. Electronic absorption spectra
were recorded on Perkin-Elmer Lambada 40 spectrophotometer. Elemental analyses were carried out
at the Microanalytical Laboratory of Cairo University, Giza, Egypt. 2,3-Diamino-quinazoline-4-one 1
was prepared as previously described [25].
4-Phenyl-1,3-dihydro-[1,2,4]triazepino[2,3-a]quinazoline-2,7-dione (4). A mixture of 2,3-diamino-
quinazolin-4-one (1, 1.76 g, 10 mmol) and ethyl benzoylacetate (2, 2.4 g, 3 mL, 20 mmol) in acetic
acid (20 mL) was refluxed for 30 h and cooled. The solid that precipitated was collected and
crystallized from ethanol to give compound 4 as yellow crystalline solid, yield (40%). mp. 282–284 °C.
1H-NMR (DMSO-d6)  4.56 (s, 2H, CH2), 7.35–8.22 (m, 9H, ArH), 13.15 (s, 1H, NH). MS m/z (%)
305 (M+ + 1, 1), 304 (M+, 10), 176 (13), 157 (18), 144 (32), 104 (46), 77 (77), 76 (100). Anal. Calcd
for C17H12N4O2 (304.30): C, 67.10; H, 3.97; N, 18.41; Found: C, 67.24; H, 3.86; N, 18.25%.
3.2. General Procedure for Synthesis of 3-Arylhydrazono-4-phenyl-[1,2,4]triazepino[2,3-a]
quinazoline-2,7(1H)-diones (6a–j).
To a stirred solution of compound 4 (1.52 g, 5 mmol) in ethanol (40 mL) was added sodium
hydroxide (0.2 g, 5 mmol) and the mixture was cooled in an ice bath at 0–5 °C. To the resulting
solution, while being stirred, was added dropwise over a period of 20 min, a solution of the appropriate
arenediazonium chloride, prepared as usual by diazotizing the respective aniline (5 mmol) in
hydrochloric acid (6 M, 3 mL) with sodium nitrite (1 M, 5 mL). The whole mixture was then left in a
refrigerator overnight. The precipitated solid was collected, washed with water and finally crystallized
from ethanol to give the respective hydrazones 6a–j.
3-(4-Methoxyphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione
(6a).
1
This compound was obtained as red solid, (68%). mp. 246–248 °C. H-NMR (DMSO-d6)  3.82 (s,
3H, OCH3), 6.92 (d, J = 9 Hz, 2H, ArH), 7.07–7.910 (m, 9H, ArH), 7.92 (d, J = 9 Hz, 2H, ArH), 12.20
(s, 1H, NH), 13.44 (s, 1H, NH); IR (KBr) νmax 3400, 3147 (2NH), 1705, 1681 (2CO) cm−1. MS m/z
(%) 439 (M+ + 1, 2), 438 (M+, 7), 122 (14), 105 (100), 77 (41). Anal. Calcd for C24H18N6O3 (438.44):
C, 65.75; H, 4.14; N, 19.17; Found: C, 65.64; H, 4.10; N, 19.09%.
3-(4-Methylphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6b). This
compound was obtained as brown solid, (69%). mp. 232–236 °C. 1H NMR (DMSO-d6)  2.45 (s, 3H,
CH3), 7.05 (d, J = 8 Hz, 2H, ArH), 7.14–7.94 (m, 9H, ArH), 8.26 (d, J = 8 Hz, 2H, ArH), 12.07 (s, 1H,
NH), 13.84 (s, 1H, NH); 13C NMR(DMSO-d6)  20.30, 113.39, 114.36, 115.87, 116.63, 121.40,
122.73, 125.15, 126.52, 127.28, 127.99, 128.93, 129.91, 131.48, 132.09, 138.53, 140.31, 159.41,

Molecules 2012, 17
8489
163.77, 164.25. IR (KBr) νmax 3471, 3406 (2NH), 1697, 1651 (2CO) cm−1. MS m/z (%) 422 (M+, 31),
317 (5 ), 211 (7), 105 (100), 90 (18), 77 (44). Anal. Calcd for C24H18N6O2 (422.44): C, 68.24; H, 4.29;
N, 19.89; Found: C, 68.17; H, 4.31; N, 19.74%.
3-(3-Methylphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6c). This
compound was obtained as yellow solid, (59%). mp. 200–204 °C. 1H-NMR (DMSO-d6)  2.24 (s, 3H,
CH3), 6.84–8.30 (m, 13H, ArH), 11.90 (s, 1H, NH), 13.33 (s, 1H, NH); IR (KBr) νmax 3433, 3100
(2NH), 1712, 1685 (2CO) cm−1. MS m/z (%) 422 (M+, 10), 211 (11), 130 (10), 105 (100), 90 (12),
77 (55). Anal. Calcd for C24H18N6O2 (422.44): C, 68.24; H, 4.29; N, 19.89; Found: C, 68.10; H, 4.21;
N, 19.68%.
3-Phenylazohydrazono-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione
(6d).
This
1
compound was obtained as yellow solid, (82%). mp. 244–246 °C. H NMR (DMSO-d6)  7.03–8.30
13
(m, 14 H, ArH), 11.90 (s, 1H, NH), 13.50 (s, 1H, NH); C NMR (DMSO-d6)  112.31, 115.23,
117.11, 120.95, 123.06, 124.19, 125.06, 126.34, 128.34, 129.07, 131.11, 132.26, 136.44, 138.60,
141.36, 156.20, 159.92, 161.23, 162.15. IR (KBr) νmax 3471, 3178 (2NH), 1700, 1654 (2CO) cm−1. MS
m/z (%) 408 (M+, 64), 407 (71), 144 (25), 134 (15), 105 (84), 91 (100), 77 (76). Anal. Calcd for
C23H16N6O2 (408.41): C, 67.64; H, 3.95; N, 20.58; Found: C, 67.50; H, 4.09; N, 20.38%.
3-(3-Chlorophenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6e). This
1
compound was obtained as yellow solid, (75%). mp. 180–182 °C. H-NMR (DMSO-d6)  7.34–8.19
(m, 13H, ArH), 11.32 (s, 1H, NH), 13.22 (s, 1H, NH); IR (KBr) νmax 3401, 3100 (2NH), 1689, 1654
(2CO) cm−1. MS m/z (%) 444 (M+ + 2, 1), 443 (M+ + 1, 4), 442 (M+, 3), 211 (15), 122 (16), 111 (6),
104 (100), 90 (10), 76 (50). Anal. Calcd for C23H15ClN6O2 (442.86): C, 62.38; H, 3.41; N, 18.98;
Found: C, 62.29; H, 3.34; N, 18.79%.
3-(4-Chlorophenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6f). This
1
compound was obtained as yellow solid, (80%). mp. 240–242 °C. H-NMR (DMSO-d6)  7.12–7.95
(m, 9H, ArH), 8.05 (d, J = 8 Hz, 2H, ArH), 8.18 (d, J = 8 Hz, 2H, ArH), 11.82 (s, 1H, NH), 13.20 (s,
13
1H, NH); C NMR(DMSO-d6)  115.23, 117.17, 118.01, 122.84, 125.29, 126.20, 127.03, 128.42,
129.18, 129.56, 131.30, 132.16, 137.54, 138.19, 142.30, 154.36, 158.90, 162.21, 163.56. IR (KBr) νmax
3282, 3186, (2NH), 1681, 1647 (2CO) cm−1. MS m/z (%) 444 (M+ + 2, 2), 442 (M+, 5), 304 (83), 276
(33), 130 (11), 111 (2), 105 (100), 89 (14), 76 (87). Anal. Calcd for C23H15ClN6O2 (442.86): C, 62.38;
H, 3.41; N, 18.98; Found: C, 62.19; H, 3.25; N, 18.88%.
3-(3-Nitrophenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6g). This
1
compound was obtained as yellowish brown solid, (64%). mp. 286–288 °C. H-NMR (DMSO-d6)
 7.10–8.15 (m, 12H, ArH), 8.33 (s, 1H, ArH), 11.39 (s, 1H, NH), 13.61 (s, 1H, NH); IR (KBr) νmax
3440, 3224 (2NH), 1700, 1651 (2C=O) cm−1. MS m/z (%) 453 (M+, 15), 144 (12), 118 (15), 105 (100),
91 (23), 76 (54). Anal. Calcd for C23H15N7O4 (453.41): C, 60.93; H, 3.33; N, 21.62; Found: C, 60.85;
H, 3.21; N, 21.49%.

Molecules 2012, 17
8490
3-(4-Nitrophenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6h). This
compound was obtained as dark red solid, (76%). mp. 268–270 °C. 1H-NMR (DMSO-d6)  7.13–7.30
and 7.44–8.01 (m, 9H, ArH), 7.33 (d, J = 8 Hz, 2H, ArH), 8.27 (d, J = 8 Hz, 2H, ArH), 11.54 (s, 1H,
13
NH), 13.52 (s, 1H, NH); C NMR(DMSO-d6)  113.95, 120.77, 125.22, 127.30, 128.41, 128.89,
130.0, 132.29, 133.46, 134.71, 135.31, 136.61, 141.56, 143.02, 144.21, 148.78, 159.0, 162.26, 162.85.
IR (KBr νmax 3440, 3379 (2NH), 1698, 1658 (2C=O) cm−1. MS m/z (%) 454 (M+ + 1, 2), 453 (M+, 25),
211 (13), 145 (9), 105 (100), 76 (52). Anal. Calcd for C23H15N7O4 (453.41): C, 60.93; H, 3.33; N,
21.62; Found: C, 60.79; H, 3.25; N, 21.71%.
3-(4-Acetylphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6i). This
compound was obtained as reddish brown solid, (71%). mp. 176–178 °C. 1H-NMR (DMSO-d6)  2.25
(s, 3H, COCH3), 7.08 (d, J = 8 Hz, 2H, ArH), 7.38–7.94 (m, 9H, ArH), 8.06 (d, J = 8 Hz, 2H, ArH),
13
11.96 (s, 1H, NH), 12.40 (s, 1H, NH); C-NMR (DMSO-d6)  55.29, 114.0, 114.60, 114.89, 115.32,
119.32, 125.05, 126.10, 127.91, 129.32, 129.83, 131.82, 132.11, 136.69, 138.66, 150.78, 155.05,
155.52, 156.81, 157.11, 190.26. IR (KBr) νmax 3429, 3356 (2NH), 1715, 1698, 1658 (3C=O) cm−1. MS
m/z (%) 451 (M+ + 1, 1), 450 (M+, 5), 303 (21), 104 (100), 76 (41). Anal. Calcd for C25H18N6O3
(450.45): C, 66.66; H, 4.03; N, 18.66; Found: C, 66.48, H, 4.20, N, 18.50%.
3-(4-Ethoxycarbonylphenylhydrazono)-4-phenyl-[1,2,4]triazepino[2,3-a]quinazoline-2,7(1H)-dione (6j).
This compound was obtained as reddish brown solid, (75%). mp. 180–182 °C 1H-NMR (DMSO-d6) 
1.30 (t, J = 7 Hz, 3H, CH3 ), 4.26 (q, J = 7 Hz, 2H, CH2), 7.23 (d, J = 8 Hz, 2H, ArH), 7.43–7.99 (m,
9H, ArH), 8.26 (d, J = 8 Hz, 2H, ArH), 11.10 (s, 1H, NH), 12.12 (s, 1H, NH); IR (KBr) νmax 3394,
3150 (2NH), 1725, 1681, 1643 (3C=O) cm−1. MS m/z (%) 481 (M+ + 1, 3), 480 (M+, 16), 479 (10),
105 (100), 104 (17), 77 (43). Anal. Calcd for C26H20N6O4 (480.47): C, 64.99; H, 4.20.; N, 17.49;
Found: C, 64.84, H, 4.10, N, 17.35%.
3.2. Agar Diffusion Well Method to Determine the Antimicrobial Activity
The microorganism inoculums were uniformly spread using sterile cotton swab on a sterile Petri
dish containing Malt extract agar (for fungi) and nutrient agar (for bacteria). Each sample (100 μL)
was added to each well (6 mm diameter holes cut in the agar gel, 20 mm apart from one another). The
systems were incubated for 24–48 h at 37 °C (for bacteria) and at 28 °C (for fungi). After incubation,
microorganism growth was observed. Inhibition of the bacterial and fungal growth were measured in
mm. Tests were performed in triplicate p [31].
4. Conclusions
In this report, a simple method for the synthesis of 3-arylhydrazono-4-phenyl-[1,2,4]triazepino[2,3-a]-
quinazoline-2,7(1H)-dione was accomplished by the coupling of 4-phenyl-1,3-dihydro[1,2,4]-
triazepino[2,3-a]quinazolin-2,7-dione and the diazonium salt of aniline derivatives. The tautomeric
structure of the products was investigated. Their spectral data indicate collectively that such
compounds exist predominantly in the hydrazone tautomeric form 6A. In addition, the antimicrobial

Molecules 2012, 17
8491
activity of some of the products showed moderate activities against E. coli and S. aureus although
these activities are far less than those of the studied reference drugs (tetracycline and amphotericin B).
References
1. Maillard-Boyer, M.; Castera-Ducros, C.; Verhaeghe, P.; Sifredi, F.; Rathelot, P.; Vanelle, P.
Access to original vinylic chlorides in the quinazoline series via a monoelectronic transfer
reaction approach. Molecules 2010, 15, 2719–2729.
2. Laddha, S.S.; Bhatnagar, S.P. Novel fused quinazolinones: Further studies on the anticonvulsant
activity of 1,2,9,11-tetrasubstituted-7H-thieno[2′,3′:4,5]pyrimido[6,1-b]-quinazolin-7-one and
1,3,10,12-tetrasubstituted-8H-pyrido[2′,3′:4,5]pyrimido[6,1-b]quinazolin-8-one. Future Med. Chem.
2010, 2, 565–573.
3. Rohini, R.; Shanker, K.; Reddy, M.P.; Ravinder, V. Synthesis and antimicrobial activities of a
new class of 6-arylbenzimidazo[1,2-c]quinazolines. J. Braz. Chem. Soc. 2010, 21, 49–57.
4. Saeed, A.; Shaheen, U.; Bolte, M. Synthesis, characterization and crystal structure of some novel
1-aryl-2-thioxo-2,3-dihydro-1H-quinazolin-4-ones. J. Chin. Chem. Soc. 2010, 57, 82–88.
5. Shakhadoyatov, K.M.; Yangibaev, S.; Yun, L.M.; Kadyrov, C.S. Synthesis and alkylation of
2-mercapto-4-quinazolone and the fungicidal activities of the compounds obtained. Chem. Nat.
Comp. 1982, 18, 106–109.
6. El-Tombary, A.A.; Ismail, K.A.; Aboulwafa, O.M.; Omar, A.M.; El-Azzouni, M.Z.;
El-Mansoury, S.T. Novel triazolo[4,3-a]quinazolinone and bis-triazolo[4,3-a:4,3'-c]quinazolines:
synthesis and antitoxoplasmosis effect. Il Farmaco 1999, 54, 486–488.
7. Gürsoy, A.; Karali, N. Synthesis and primary cytotoxicity evaluation of 3-[[(3-phenyl-4(3H)-
quinazolinone-2-yl)mercaptoacetyl]hydrazono]-1H-2-indolinones. Eur. J. Med. Chem. 2003, 38,
633–643.
8. Hamel, E.; Lin, C.M.; Plowman, J.; Wang, H.K.; Lee, K.H.; Paull, K.D. Antitumor 2,3-dihydro-2-
(aryl)-4(1H)-quinazolinone derivatives: Interactions with tubulin. Biochem. Pharmacol. 1996, 51,
53–59.
9. Xia, Y.; Yang, Z.Y.; Hour, M.-J.; Kuo, S.C.; Xia, P.; Bastow, K.F.; Nakanishi, Y.; Nampoothiri, P.;
Hackl, T.; Hamel, E.; Lee, K. H. Antitumor agents. Part 204: Synthesis and biological evaluation
of substituted 2-aryl quinazolinones. Bioorg. Med. Chem. Lett. 2001, 11, 1193–1196.
10. Peet, N.P.; Baugh, L.E.; Sundler, S.; Lewis, J.E.; Matthews, E.H.; Olberding, E.L.; Shah, D.N.
3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinone sodium salt (MDL 427): A new antiallergic agent.
J. Med. Chem. 1986, 29, 2403–2409.
11. Cross, P.E.; Dickison, R.P.; Parry, M.J.; Randall, M.J. Selective thromboxane synthetase
inhibitors. 1. 1-[(aryloxy)alkyl]-1H-imidazoles. J. Med. Chem. 1985, 28, 1427–1432.
12. Hankovszky, H.O.; Hideg, K.; Bódi, I.; Frank, L. New antiarrhythmic agents. 2,2,5,5-
Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-tetramethyl-pyrrolidine-3-carboxamides.
J. Med. Chem. 1986, 29, 1138–1152.
13. Van Dyck, C.H.; Tan, P.-Z.; Baldwin, R.M.; Amici, L.A.; Garg, P.K.; Ng, C.K.; Soufer, R.;
Charney, D.S.; Innis, R.B. PET quantification of 5-HT2A receptors in the human brain: a constant
infusion paradigm with [18F]altanserin. J. Nucl. Med. 2000, 41, 234–241.

Molecules 2012, 17
8492
14. Du, X.; Jiang, Y.; Qian, W.; Lu, X.; Walsh, J.P. Fatty acids inhibit growth-factor-induced
diacylglycerol kinase alpha activation in vascular smooth-muscle cells. Biochem. J. 2001, 1,
275–282.
15. Santagati, A.; Modica, M.; Monsu Scolaro, L.; Santagati, M. New synthetic approaches to fused
heterocyclo-quinazolines. J. Chem. Res. (s) 1999, 86–87.
16. Barghash, A.E.M.; El-Kerdawy, M.M.; Shehata, I.A.; Abdel-Aziz, N.I. Synthesis and antiviral
testing of certain derivatives of thiazolo[4,3-b]benzothiazoles, thiazolo[3′,4′:2,3][1,2,4]-
triazolo[5,1-b]-, {triazino [3,2-b]- and triazepino[3,2-b]}-quinazolines. Alex. J. Pharm. Sci. 2004,
18, 109–113.
17. Tiwari, V.K.; Kale, R.R.; Mishra, B.B.; Singh, A. A facile one-pot MW approach for N3-
(heteroaryl-2’-yl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one. ARKIVOC 2008, 14, 27–36.
18. Mosselhi, M.A.; Pfleiderer, W. Syntheses, properties, and reactions of 8-aminoxanthines, purines.
Part XVI: Syntheses, properties, and reactions of 8-aminoxanthines. Helv. Chim. Acta 2010, 93,
2115–2134.
19. Shawali, A.S.; Mosselhi, M.A.; Altablawy, F.M.A.; Farghaly, T.A.; Tawfik, N.M. Synthesis and
tautomeric structure of 3,7-bis(arylazo)-6-methyl-2-phenyl-1H-imidazo[1,2-b]pyrazoles in ground
and excited states. Tetrahedron 2008, 64, 5524–5530.
20. Shawali, A.S.; Mosselhi, M.A.; Farghaly, T.A.; Shehata, M.R.; Tawfik, N.M. Synthesis and
tautomeric structure of 3,6-bis(arylazo)pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-diones. J. Chem. Res.
2008, 452–456.
21. Shawali, A.S.; Mosselhi, M.A.; Farghaly, T.A. Synthesis and tautomeric structure of 2-arylazo-
4H-imidazo[2,1-b][1,3,4]-thiadiazines. J. Chem. Res. 2007, 479–483.
22. Shawali, A.S.; Abdallah, M.A.; Mosselhi, M.A.N.; Mohamed, Y.F. Synthesis and tautomeric
structure of 1,2-bis(7-arylhydrazono-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl)ethanes.
Z. Naturforsch. B: Chem. Sci. 2002, 552–556.
23. Mosselhi, M.N.; Abdallah, M.A.; Mohamed, Y.F.; Shawali, A.S. Synthesis and tautomeric
structure of 7-arylhydrazono-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines. Phosphorus Sulfur
Silicon 2002, 177, 487–496.
24. Mosselhi, M.A.N.; Abdallah, M.A.; Riyadh, S.M.; Harhash, A.E.; Shawali, A.S. Tautomerism and
reactions of 1H-1,2,4-thiazole-5-thiones with hydrazonoyl halides, J. Prakt. Chem. 1998, 340,
160–164.
25. Hlavka, J.J.; Bitha, P.; Lin, Y.; Strohmeyer, T. Synthesis and reactions of 2,3-diamino-4(3H)-
pyrimidinones and 3-amino-2-hydrazino-4(3H)-pyrimidinones. J. Heterocycl. Chem. 1984, 21,
1537–1541.
26. Essassi, E.M.; Lavergne, J.P.; Viallefont, P.; Daunis, J. Recherches en série triazepine-1,2,4:
1-détermination de la structure de la triazolotriazépinone obtenue par action de l'acétylacétate
d'éthyle sur le diamino-3,4 triazole-1,2,4. J. Heterocycl. Chem. 1975, 12, 661–663.
27. Hassan, K.M.; Ahmed, R.A.; Abdel-Hafez, S.H.; Abdel-Azim, M.A. Condensed
thioxocyclopentapyridine (isoquinoline)-1,2,4-azines. Phosphorus Sulfur Silicon 2006, 181,
481–496.
28. Romano, C.; De La Cuesta, E.; Avendano, C.; Florencio, F.; Sainz-Aparicio, J. Reactions of
1,2-diaminobenzimidazoles with β-dicarbonyl compounds. Tetrahedron 1988, 44, 7185–7192.

Molecules 2012, 17
8493
29. Shawali, A.S.; Sherif, S.M.; Farghaly, T.A.; Shehata, M.R.; Darwish, M.A.A. Synthesis and
tautomeric structure of the azo-coupling products of 2-methyl-7-phenylpyrimido[1,2-
b][1,2,4]triazepine-4,9(3H,5H)-dione. J. Chem. Res. 2007, 44–47.
30. Jones, R.; Ryan, A.J.; Sternhell, S.; Wright, S.E. The structures of some 5-pyrazolones and
derived 4-arylazo-5-pyrazolones. Tetrahedron 1963, 19, 1497–1507.
31. Smania, J.A.; Monache, F.D.; Smania, E.F.A.; Cuneo, R.S. Antibacterial activity of steroidal
compounds isolated from Ganoderma applanatum (Pers.) Pat. (Aphyllophoromycetideae) fruit
body. Int. J. Med. Mushrooms 1999, 1, 325–330.
Sample Availability: Samples of the compounds 4 and 6 are available from the authors.
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).